Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C

Eiji Tsujita, Yo Ichi Yamashita, Kazuki Takeishi, Takashi Maeda, Shin Ichiro Takaki, Nanti Mori, Yasuyuki Aisaka, Yoshinari Furukawa, Ken Shirabe, Teruyoshi Ishida, Yoshihiko Maehara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aims: Interferon (IFN) improves the prognosis of HCV-related hepatocellular carcinoma (HCC) in patients. However, the effects of IFN therapy for second hepatectomy (Hx) for recurrent HCC have not been established. Methodology: Subjects included 96 patients who underwent a second Hx for recurrence of HCV-related HCC. Forty-four patients received IFN therapy past or postoperatively of the first Hx. Twenty of those patients attained a sustained viral response (SVR). The other 24 were non-responders (NR) and 52 patients who had not received IFN therapy (non-lFN) were classified as the NR/non-IFN group. Results: Overall survival (SVR group vs. NR/non-IFN group: 5-yr, 91.7 vs. 51.0%; p = 0.012) and disease-free survival (SVR group vs. NR/non-IFN group: 3-yr, 64.7 vs. 25.9%; p = 0.006) rates were significantly different in both groups. By multivariate analysis, NR/non-IFN therapy, was the independent risk factor for overall survival (p = 0.025) and disease-free survival (p = 0.006) after second Hx. Conclusions: SVR achieved past or postoperatively of the first Hx of HCV-related HCC significantly inhibits recurrence and consequently improves patient survival after second Hx for recurrent HCC. Patients with SVR to IFN therapy would be good candidates for second Hx for recurrent HCC.

Original languageEnglish
Pages (from-to)2048-2054
Number of pages7
JournalHepato-gastroenterology
Volume60
Issue number128
DOIs
Publication statusPublished - Nov 1 2013

Fingerprint

Hepatectomy
Hepatitis C
Interferons
Hepatocellular Carcinoma
Therapeutics
Disease-Free Survival
Survival
Recurrence
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C. / Tsujita, Eiji; Yamashita, Yo Ichi; Takeishi, Kazuki; Maeda, Takashi; Takaki, Shin Ichiro; Mori, Nanti; Aisaka, Yasuyuki; Furukawa, Yoshinari; Shirabe, Ken; Ishida, Teruyoshi; Maehara, Yoshihiko.

In: Hepato-gastroenterology, Vol. 60, No. 128, 01.11.2013, p. 2048-2054.

Research output: Contribution to journalArticle

Tsujita, E, Yamashita, YI, Takeishi, K, Maeda, T, Takaki, SI, Mori, N, Aisaka, Y, Furukawa, Y, Shirabe, K, Ishida, T & Maehara, Y 2013, 'Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C', Hepato-gastroenterology, vol. 60, no. 128, pp. 2048-2054. https://doi.org/10.5754/hge13382
Tsujita, Eiji ; Yamashita, Yo Ichi ; Takeishi, Kazuki ; Maeda, Takashi ; Takaki, Shin Ichiro ; Mori, Nanti ; Aisaka, Yasuyuki ; Furukawa, Yoshinari ; Shirabe, Ken ; Ishida, Teruyoshi ; Maehara, Yoshihiko. / Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C. In: Hepato-gastroenterology. 2013 ; Vol. 60, No. 128. pp. 2048-2054.
@article{c784bce769e247f1b6cc2658236f9fae,
title = "Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C",
abstract = "Background/Aims: Interferon (IFN) improves the prognosis of HCV-related hepatocellular carcinoma (HCC) in patients. However, the effects of IFN therapy for second hepatectomy (Hx) for recurrent HCC have not been established. Methodology: Subjects included 96 patients who underwent a second Hx for recurrence of HCV-related HCC. Forty-four patients received IFN therapy past or postoperatively of the first Hx. Twenty of those patients attained a sustained viral response (SVR). The other 24 were non-responders (NR) and 52 patients who had not received IFN therapy (non-lFN) were classified as the NR/non-IFN group. Results: Overall survival (SVR group vs. NR/non-IFN group: 5-yr, 91.7 vs. 51.0{\%}; p = 0.012) and disease-free survival (SVR group vs. NR/non-IFN group: 3-yr, 64.7 vs. 25.9{\%}; p = 0.006) rates were significantly different in both groups. By multivariate analysis, NR/non-IFN therapy, was the independent risk factor for overall survival (p = 0.025) and disease-free survival (p = 0.006) after second Hx. Conclusions: SVR achieved past or postoperatively of the first Hx of HCV-related HCC significantly inhibits recurrence and consequently improves patient survival after second Hx for recurrent HCC. Patients with SVR to IFN therapy would be good candidates for second Hx for recurrent HCC.",
author = "Eiji Tsujita and Yamashita, {Yo Ichi} and Kazuki Takeishi and Takashi Maeda and Takaki, {Shin Ichiro} and Nanti Mori and Yasuyuki Aisaka and Yoshinari Furukawa and Ken Shirabe and Teruyoshi Ishida and Yoshihiko Maehara",
year = "2013",
month = "11",
day = "1",
doi = "10.5754/hge13382",
language = "English",
volume = "60",
pages = "2048--2054",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "128",

}

TY - JOUR

T1 - Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C

AU - Tsujita, Eiji

AU - Yamashita, Yo Ichi

AU - Takeishi, Kazuki

AU - Maeda, Takashi

AU - Takaki, Shin Ichiro

AU - Mori, Nanti

AU - Aisaka, Yasuyuki

AU - Furukawa, Yoshinari

AU - Shirabe, Ken

AU - Ishida, Teruyoshi

AU - Maehara, Yoshihiko

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Background/Aims: Interferon (IFN) improves the prognosis of HCV-related hepatocellular carcinoma (HCC) in patients. However, the effects of IFN therapy for second hepatectomy (Hx) for recurrent HCC have not been established. Methodology: Subjects included 96 patients who underwent a second Hx for recurrence of HCV-related HCC. Forty-four patients received IFN therapy past or postoperatively of the first Hx. Twenty of those patients attained a sustained viral response (SVR). The other 24 were non-responders (NR) and 52 patients who had not received IFN therapy (non-lFN) were classified as the NR/non-IFN group. Results: Overall survival (SVR group vs. NR/non-IFN group: 5-yr, 91.7 vs. 51.0%; p = 0.012) and disease-free survival (SVR group vs. NR/non-IFN group: 3-yr, 64.7 vs. 25.9%; p = 0.006) rates were significantly different in both groups. By multivariate analysis, NR/non-IFN therapy, was the independent risk factor for overall survival (p = 0.025) and disease-free survival (p = 0.006) after second Hx. Conclusions: SVR achieved past or postoperatively of the first Hx of HCV-related HCC significantly inhibits recurrence and consequently improves patient survival after second Hx for recurrent HCC. Patients with SVR to IFN therapy would be good candidates for second Hx for recurrent HCC.

AB - Background/Aims: Interferon (IFN) improves the prognosis of HCV-related hepatocellular carcinoma (HCC) in patients. However, the effects of IFN therapy for second hepatectomy (Hx) for recurrent HCC have not been established. Methodology: Subjects included 96 patients who underwent a second Hx for recurrence of HCV-related HCC. Forty-four patients received IFN therapy past or postoperatively of the first Hx. Twenty of those patients attained a sustained viral response (SVR). The other 24 were non-responders (NR) and 52 patients who had not received IFN therapy (non-lFN) were classified as the NR/non-IFN group. Results: Overall survival (SVR group vs. NR/non-IFN group: 5-yr, 91.7 vs. 51.0%; p = 0.012) and disease-free survival (SVR group vs. NR/non-IFN group: 3-yr, 64.7 vs. 25.9%; p = 0.006) rates were significantly different in both groups. By multivariate analysis, NR/non-IFN therapy, was the independent risk factor for overall survival (p = 0.025) and disease-free survival (p = 0.006) after second Hx. Conclusions: SVR achieved past or postoperatively of the first Hx of HCV-related HCC significantly inhibits recurrence and consequently improves patient survival after second Hx for recurrent HCC. Patients with SVR to IFN therapy would be good candidates for second Hx for recurrent HCC.

UR - http://www.scopus.com/inward/record.url?scp=84893711558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893711558&partnerID=8YFLogxK

U2 - 10.5754/hge13382

DO - 10.5754/hge13382

M3 - Article

C2 - 24088310

AN - SCOPUS:84893711558

VL - 60

SP - 2048

EP - 2054

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 128

ER -